Login to Your Account

Milestone for Array; Astrazeneca Starts Phase III NSCLC Trial

By Peter Winter
BioWorld Insight Editor

Wednesday, October 23, 2013
Boulder, Colo.-based Array Biopharma Inc. will be receiving a $5 million milestone payment following the announcement that Astrazeneca plc has begun a Phase III trial for selumetinib, an oral MEK inhibitor, being investigated as second-line therapy in patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription